期刊文献+

同型半胱氨酸水平与女性绝经期骨质疏松相关性研究

Correlative Research of the Homocysteine Levels with Osteoporosis in Postmenopausal Women
原文传递
导出
摘要 目的:通过分析女性绝经期不同骨密度人群的血浆同型半胱氨酸(HCY)指标,探讨同型半胱氨酸在女性绝经期骨质疏松发生过程中的作用及其潜在的临床价值。方法:收集2014年3月至2016年3月我院体检中心进行体检的女性绝经期妇女(>60岁)血样标本共计625例,根据体检的骨密度报告对其进行分组,骨质疏松组215例,骨量减少组309例,骨量正常组101例,测量每组的同型半胱氨酸水平。结果:骨密度程度与同型半胱氨酸水平存在负相关关系(rs=-0.763,P=0.046),三组之间的同型半胱氨酸水平也存在显著差异(F=4.807,P<0.016),其中骨质疏松组指标最高,骨量正常组指标最低。结论:同型半胱氨酸是重要的骨代谢指标,在衡量绝经期妇女骨质疏松进展中具有重要的意义。 Objective:By analyzing the different bone mineral density in postmenopausal women crowd plasma homocysteine (HCy) indicators on the role of homocysteine in the process of osteoporosis in postmenopausal women and its potential clinical value.Methods:Collected from March 2014 to March 2016 XX Hospital Medical Center for medical examination of female postmenopausal women (〉 60 years) blood samples totaling 625 cases,according to the medical report of their bone density group,osteoporosis group of 215 cases,osteopenia group of 309 cases,101 cases of normal bone mass,measuring homocysteine levels for each group.Results:Between the three groups of homocysteine levels were significantly different (P〈0.05),in which the highest set of indicators ofosteoporosis,bone mass index normal minimum.Conclusion:Homocysteine is an important indicator of bone metabolism,and has important significance in postmenopausal women with osteoporosis to measure progress.
出处 《现代生物医学进展》 CAS 2017年第19期3672-3674,共3页 Progress in Modern Biomedicine
基金 首都卫生发展科研专项基金项目(2016-2-2113)
关键词 绝经期 骨质疏松 同型半胱氨酸 骨转化指标 骨密度 Menopause Osteoporosis Homocysteine Bone turnover markers Bone mineral density
  • 相关文献

参考文献6

二级参考文献73

  • 1安胜军,杨学辉,李恩.雌激素与骨质疏松症[J].中国骨质疏松杂志,1999,5(3):77-85. 被引量:13
  • 2曾芳馨,熊中云.抗酒石酸酸性磷酸酶与骨代谢[J].华西医学,2005,20(3):545-545. 被引量:8
  • 3程晓光(译),刘忠厚(校).国际临床骨密度学会共识文件(2005年版)[J].中国骨质疏松杂志,2006,12(2):205-209. 被引量:68
  • 4梁少俊,刘宏,杨力,蔡德鸿.绝经后骨质疏松与血清OPG及RANKL关系的研究[J].广东医学,2006,27(5):669-671. 被引量:11
  • 5白旭华.雌激素与绝经后骨质疏松症关系的研究进展[J].内蒙古民族大学学报(自然科学版),2007,22(2):180-182. 被引量:19
  • 6Yano K,Tsuda E,Washida N,et al.Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor:increased serum concentrations in postmenopausal women with osteoporosis[J].J Bone Miner Res,1999,14(4):518-527.
  • 7Rogers A,Saleh G,Hannon RA,et al.Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women[J].J Clin Endoerinol Metab,2002,87(10):4470-4475.
  • 8Mezquita-Raya P,de la Hiquera M,García DF,et al.The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women[J].Osteoporos Int,2005,16(11):1368-1374.
  • 9Hobfauer LC,Heufelder AE.Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology[J].J Mol Med(Berl),2001,79(5-6):243-253.
  • 10Zheng SX,Vrindts Y,Lopez M,et al.Increase in cytokine production (IL-1 beta,IL-6,TFN-alpha but not INF-gamma,GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis[J].Maturitas,1997,26(1):63-71.

共引文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部